

R&D

EFPIA Disclosure Report – 2024 Data – Norway

| Data disclosure form (Currency NOK) | | | | | | | | | | | | | |
|--|---|---|-------------------------------|----------------------------|---|------------------------------|--|-------------------|------------------------|---------------------------------|--|---------------------|--|
| HCP/HCO Disclosure Date of publication: 27/06/2025 | | | | | | | | | | | | | |
| | Full name | HCPs: City of Principal Practice HCOs: City where registered | Country of Principal Practice | Principal Practice Address | Unique country identifier (OPTIONAL) | Donations and Grants to HCOs | Contribution to costs of Events | | | Fee for service and consultancy | | | |
| | | | | | | | Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event | Registration Fees | Travel & Accommodation | Fees | Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract | TOTAL (OPTIONAL) | |
| | INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: Itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate) | | | | | | | | | | | | |
| | JOHNSEN, JON | VETTRE | Norway | STRANDVEIEN 35 | | | | | | 29,091.00 | 73.00 | 29,164.00 | |
| | KVINGE, SIV KJELSÅS | RØYKEN | Norway | HYGGENVEIEN 25 | | | | | | 5,000.00 | 1,894.55 | 6,894.55 | |
| HCPs | OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons | | | | | | | | | | | | |
| | Aggregate amount attributable to transfers of value to such Recipients | | | | | | | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| | Number of Recipients in aggregate disclosure | | | | | | | 0 | 0 | 0 | 0 | 0 | |
| | % of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed | | | | | | | 0% | 0% | 0% | 0% | 0% | |
| | INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate) | | | | | | | | | | | | |
| | NORSK NYREMEDISINSK FORENING | OSLO | Norway | KIRKEGATA 25 | | | 56140.00 | | | | | 56,140.00 | |
| | NORSK SELSKAP FOR HEMATOLOGI | OSLO | Norway | KIRKEGATA 25 | | | 21250.00 | | | | | 21,250.00 | |
| | SCORPION AS | TRONDHEIM | Norway | EIRIK JARSGT.3 | | | | | | | 2,847.46 | 2,847.46 | |
| | TRES BIOTECHNOLOGY AS | MORVIK | Norway | TORVBAKKEN 4 | | | | | | 85,789.67 | 6,144.52 | 91,934.19 | |
| | OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons | | | | | | | | | | | | |
| | Aggregate amount attributable to transfers of value to such Recipients | | | | | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Optional | |
| | Number of Recipients in aggregate disclosure | | | | | 0 | 0 | 0 | 0 | 0 | 0 | N/A | |
| | % of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed | | | | | | 0% | 0% | 0% | 0% | 0% | N/A | |
| | | | | | | | | | | | | | |

AGGREGATE DISCLOSURE
Transfers of Value re Research & Development as defined 131,408.72